Parkinson's Disease Research Today is a free monthly online journal that collates and summarizes the latest research about Parkinson's Disease, including details on symptoms, treatment, genetics, medication.

Volume 4 (2007), Issue 6 (June)

1. Action and object naming in Parkinson's disease without dementia.
   Eur J Neurol, 14(6): 632-7. [Abstract] [Full-text]
2. Quantification of trunk rotations during turning and walking in Parkinson's disease.
   Clin Neurophysiol, 118(7): 1602-6. [Abstract] [Full-text]
3. Do alpha-synuclein aggregates in autonomic plexuses predate Lewy body disorders?: a cohort study.
   Neurology, 68(23): 2012-8. [Abstract] [Full-text]
4. Thermodynamics imprinting reveals differential binding of metals to alpha-synuclein: relevance to Parkinson's disease.
   Biochem Biophys Res Commun, 359(1): 115-20. [Abstract] [Full-text]
5. Test-retest reliability of 24 hours of activity monitoring in individuals with Parkinson's disease in home and community.
   Neurorehabil Neural Repair, 21(4): 327-40. [Abstract] [Full-text]
6. A study of the relationships between Parkinson's disease and markers of traffic-derived and environmental manganese air pollution in two Canadian cities.
   Environ Res, 104(3): 420-32. [Abstract] [Full-text]
7. Rotigotine transdermal patch in the treatment of Parkinson's disease and restless legs syndrome.
   Expert Opin Pharmacother, 8(9): 1329-35. [Abstract] [Full-text]
8. Management of the behavioral aspects of Parkinson's disease.
   Expert Rev Neurother, 7(6): 711-25. [Abstract] [Full-text]
9. Intervening in the neuropsychiatric features of Parkinson's disease.
   Expert Rev Neurother, 7(6): 699-710. [Abstract] [Full-text]
10. Death in the substantia nigra: a motor tragedy.
    Expert Rev Neurother, 7(6): 677-97. [Abstract] [Full-text]
11. Stem cell therapy for Parkinson's disease.
    Expert Rev Neurother, 7(6): 667-75. [Abstract] [Full-text]
12. Genetics of Parkinson's disease and parkinsonism.
    Expert Rev Neurother, 7(6): 657-66. [Abstract] [Full-text]
13. Autosomal dominant Parkinson's disease and the route to new therapies.
    Expert Rev Neurother, 7(6): 649-56. [Abstract] [Full-text]
14. Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease.
    Expert Rev Neurother, 7(6): 637-47. [Abstract] [Full-text]
15. Inflammatory cytokine gene polymorphisms and increased risk of Parkinson disease.
    Arch Neurol, 64(6): 836-40. [Abstract] [Full-text]
16. Mutations in LRRK2/dardarin associated with Parkinson disease are more toxic than equivalent mutations in the homologous kinase LRRK1.
    J Neurochem, 102(1): 93-102. [Abstract] [Full-text]
17. Effects of subthalamic nucleus stimulation and levodopa on the autonomic nervous system in Parkinson's disease.
    J Neurol Neurosurg Psychiatry, 78(7): 742-5. [Abstract] [Full-text]
18. Usefulness of combined fractional anisotropy and apparent diffusion coefficient values for detection of involvement in multiple system atrophy.
    J Neurol Neurosurg Psychiatry, 78(7): 722-8. [Abstract] [Full-text]
19. Visual recognition memory differentiates dementia with Lewy bodies and Parkinson's disease dementia.
    J Neurol Neurosurg Psychiatry, 78(7): 738-41. [Abstract] [Full-text]
20. Autonomic dysfunction in dementia.
    J Neurol Neurosurg Psychiatry, 78(7): 671-7. [Abstract] [Full-text]
21. A randomised controlled trial of a home based exercise programme to reduce the risk of falling among people with Parkinson's disease.
    J Neurol Neurosurg Psychiatry, 78(7): 678-84. [Abstract] [Full-text]
22. Cognitive impairment patterns in Parkinson's disease with visual hallucinations.
    J Clin Neurosci, 14(8): 742-6. [Abstract] [Full-text]
23. Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson's disease.
    J Neurosci, 27(25): 6701-11. [Abstract] [Full-text]
24. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease.
    Clin Exp Pharmacol Physiol, 34(7): 555-65. [Abstract] [Full-text]
25. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort.
    Brain, 130: 1787-98. [Abstract] [Full-text]
26. Mechanisms of body weight gain in patients with Parkinson's disease after subthalamic stimulation.
    Brain, 130: 1808-18. [Abstract] [Full-text]
27. Changes in network activity with the progression of Parkinson's disease.
    Brain, 130: 1834-46. [Abstract] [Full-text]
28. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.
    Brain, 130: 1819-33. [Abstract] [Full-text]
29. Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia.
    Brain, 130: 1847-60. [Abstract] [Full-text]
30. Parkinson's disease-like midbrain sonography abnormalities are frequent in depressive disorders.
    Brain, 130: 1799-807. [Abstract] [Full-text]
31. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial.
    Lancet, 369(9579): 2097-105. [Abstract] [Full-text]
32. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity.
    Biochem J, 405(2): 307-17. [Abstract] [Full-text]
33. Nigrostriatal damage preferentially decreases a subpopulation of alpha6beta2* nAChRs in mouse, monkey, and Parkinson's disease striatum.
    Mol Pharmacol, 72(1): 52-61. [Abstract] [Full-text]
34. Prospective case-control study of nonfatal cancer preceding the diagnosis of Parkinson's disease.
    Cancer Causes Control, 18(7): 705-11. [Abstract] [Full-text]
35. Pathogenic mutations in Parkinson disease.
    Hum Mutat, 28(7): 641-53. [Abstract] [Full-text]

© 2004-2008 Parkinson's Disease Research Today. All Rights Reserved.